We are excited to announce that our Scientific Advisor, Prof. Steve Oh, will be attending and presenting the latest research findings on Smart MCs' innovative P2 dissolvable microcarriers at the upcoming ISCT 2025 conference in New Orleans. Prof. Oh's presentation will highlight the significant advancements made possible by the unique properties [...]
We were honored to host Prof. Steve Oh for our January webinar, where he presented on:"Mesenchymal Stem Cell Therapies: Promises Fulfilled and Potential New Applications."Presentation Highlights:What are MSCs?Prof. Oh explored the unique capabilities of Mesenchymal Stromal Cells (MSC), also referred to as Medicinal Signaling Cells, for their ability to produce cytokines, growth factors, and extracellular [...]
Microcarrier culture is a powerful tool for large-scale cell production, but it requires careful attention to detail to avoid common mistakes that can compromise the quality and efficiency of your culture. From seeding to harvesting, each step presents its own challenges that, if not managed properly, can lead to suboptimal results.Inconsistent Seeding Due to Poor [...]
One of the most significant advancements in drug discovery is the ability to screen bioactive compounds effectively and at scale. This is particularly important when using cells like HEK293T cells, which are difficult to produce at scale. A recent study published in the Journal of Pharmaceutical and Biomedical Analysis demonstrates how microcarrier culture can [...]
In a recent study, researchers have developed a novel microcarrier-microbioreactor platform that shows significant promise for improving the manufacturing process of mesenchymal stem and stromal cells (MSCs), which are vital for treating a range of clinical conditions. Despite the potential of MSCs, their clinical application has been hindered by challenges in achieving consistent product [...]
A recent study has shed light on a novel process intensification strategy for the expansion of human induced pluripotent stem cells (hiPSCs), which holds promise for enhancing the manufacturing of hiPSC-based therapeutics. The research focused on evaluating a one-step inoculation (OSI) approach, commonly used in antibody and vaccine production, and its potential application to [...]
Wharton’s jelly mesenchymal stem/stromal cells (WJMSCs) have gained significant attention due to their potential in immunomodulatory, anti-inflammatory, tissue repair, and regenerative therapies. These cells have shown promise in treating various clinical conditions, highlighting the need for scalable manufacturing processes to meet commercial and clinical demands. Recent research has focused on developing a robust, scalable, and [...]
We are excited to announce that our Chief Scientific Advisor, Prof. Steve Oh, PhD, will be chairing an insightful webinar on "Bioprocessing and Artificial Intelligence in Cell Therapies: China’s Model." This event is presented by the ISCT Asia Regional Executive Committee and sponsored by REGEN-αGEEK (Haining) Biotechnology Co., Ltd. Event Details: Date: Wednesday, August 7, [...]
Influenza viruses pose a significant threat to global health, with the potential to trigger pandemics. Vaccination remains the primary strategy to reduce illness and death during such outbreaks. Addressing the urgent need for readily available vaccines, a new study introduces an advanced manufacturing process for inactivated influenza H5N1 vaccines. This innovative process leverages Madin-Darby canine [...]
Check out this publication on how scaling bovine viral vaccine production can be enabled using Microcarriers: Vaccination remains the most effective method for controlling and preventing diseases, ensuring the safe trade of live animals. The manufacturing of viral vaccines, however, comes with specific challenges, particularly due to the demands of the cell substrates and [...]
